LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.
—
Filed today
—
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there — you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings —
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Indoco is selling its eye care business division to another company for Rs. 110 Crore in cash, completing paperwork today.
🤖 AI Summary
Agreement to Transfer Business executed 30th April 2026 for Rs. 110 Crores
Ophthalmic division generated Rs. 47.79 Crores revenue in FY25 — 3.2% of company total
Buyer is Sunways (India) Private Limited with FY25 standalone revenue Rs. 137.42 Crores
Sale covers India, French West Africa, Cameroon, Congo, Gabon, Kenya, Botswana, Tanzania, Zambia, Zimbabwe, Namibia
Transaction completion expected in approximately three months subject to conditions precedent
🔢 Key Numbers — exact figures from BSE filing, not rounded
Sale consideration
Rs. 110 Crores
Ophthalmic division FY25 revenue
Rs. 47.79 Crores
Division contribution to standalone revenue
3.2%
Buyer FY25 revenue (standalone)
Rs. 137.42 Crores
Expected completion timeline
Approximately 3 months
🏢 How This Affects the Company
📈
Business Impact
Ophthalmic division represented only 3.2% of standalone revenue (Rs. 47.79 Crores in FY25). Divestment removes a non-core, lower-contribution unit. Core pharma business continues unaffected.
💰
Financial Impact
Rs. 110 Crores gross consideration received, subject to adjustments. Removes Rs. 47.79 Crores annual revenue stream but generates one-time cash inflow. Net impact on standalone earnings depends on division profitability and adjustment terms.
⚙️
Operational Impact
Divestment eliminates separate ophthalmic operations, supply chain, and associated workforce in specified territories. Remaining core pharmaceutical operations continue independently.
⚠️
Risk Impact
Transaction completion contingent on conditions precedent in ATB. Failure to satisfy conditions could delay or terminate sale. Post-completion, company loses footprint in ophthalmic segment across 11 territories.
👥 What This Means For Shareholders
✅
Action Required
No action required. Transaction completion will be reported via subsequent regulation 30 disclosure.
👤
Who Is Affected
All shareholders benefit proportionally from Rs. 110 Crore cash inflow to balance sheet. No selective impact identified in filing.
🔍
Management Signal
Management prioritizes core pharmaceutical business by divesting lower-margin, non-core ophthalmic operations in multiple territories.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Regulation 30 disclosure on ATB execution confirmation with exact agreement date
Completion filing per Regulation 30 — confirm Rs. 110 Crore cash receipt and final adjustments
MEDIUM RISKTransaction completion subject to conditions precedent not detailed in filing. Adjustment mechanism for Rs. 110 Crore consideration not specified. Three-month timeline adds execution uncertainty.
💡 Investor Takeaway
Indoco has sold its ophthalmic division to Sunways for Rs. 110 Crores, generating one-time cash inflow. Division contributed Rs. 47.79 Crores revenue in FY25 (3.2% of standalone total). Completion expected in three months, subject to conditions precedent in the agreement.
⚖️ Strengths & Concerns
✅ Positives
Clear asset divestment at Rs. 110 Crores generates liquidity for core business reinvestment
Buyer Sunways has established operations — FY25 revenue Rs. 137.42 Crores — suggests capability
⚠️ Concerns
Ophthalmic division sale removes revenue stream entirely despite 3.2% contribution to standalone revenue
Transaction completion depends on undefined conditions precedent — three-month timeline remains subject to satisfaction
📅 Company Track Record
Prior intimation filed 30th April 2026 announced strategic transfer of ophthalmic division to Sunway (same date). Today's filing confirms execution of formal Agreement to Transfer Business with Sunways (India) Private Limited. Past financial track record of Indoco's ophthalmic division not detailed in prior public filings reviewed.
Based on publicly available historical data. For context only.
All BSE filings we have analysed for Indoco Remedies Ltd.
You've read one filing
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again — explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.